Literature DB >> 28660622

Palliative care access for hospitalized patients with end-stage liver disease across the United States.

Barret Rush1,2,3, Keith R Walley1,3, Leo A Celi4, Neil Rajoriya5, Mayur Brahmania2,5.   

Abstract

Patients with end-stage liver disease (ESLD) often have a high symptom burden. Historically, palliative care (PC) services have been underused in this population. We investigated the use of PC services in patients with ESLD hospitalized across the United States. We used the Nationwide Inpatient Sample to conduct a retrospective nationwide cohort analysis. All patients >18 years of age admitted with ESLD, defined as those with at least two liver decompensation events, were included in the analysis. A multivariate logistic regression model predicting referral to PC was created. We analyzed 55,208,382 hospitalizations from the 2006-2012 Nationwide Inpatient Sample, with 39,349 (0.07%) patients meeting study inclusion. PC consultation was performed in 1,789 (4.5%) ESLD patients. The rate of PC referral in ESLD increased from 0.97% in 2006 to 7.1% in 2012 (P < 0.01). In multivariate analysis, factors associated with lower referral to PC were Hispanic race (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.66-0.89; P < 0.01) and insurance coverage (OR, 0.74; 95% CI, 0.65-0.84; P < 0.01). Factors associated with increased referral to PC were age (per 5-year increase, OR, 1.05; 95% CI, 1.03-1.08; P < 0.01), do-not-resuscitate status (OR, 16.24; 95% CI, 14.20-18.56; P < 0.01), treatment in a teaching hospital (OR, 1.25; 95% CI, 1.12-1.39; P < 0.01), presence of hepatocellular carcinoma (OR, 2.00; 95% CI, 1.71-2.33; P < 0.01), and presence of metastatic cancer (OR, 2.39; 95% CI, 1.80-3.18; P < 0.01). PC referral was most common in west coast hospitals (OR, 1.81; 95% CI, 1.53-2.14; P < 0.01) as well as large-sized hospitals (OR, 1.49; 95% CI, 1.22-1.82; P < 0.01).
CONCLUSION: From 2006 to 2012 the use of PC in ESLD patients increased substantially; socioeconomic, geographical, and ethnic barriers to accessing PC were observed. (Hepatology 2017;66:1585-1591).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28660622     DOI: 10.1002/hep.29297

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study.

Authors:  Nneka N Ufere; John Donlan; Lauren Waldman; Arpan Patel; Jules L Dienstag; Lawrence S Friedman; Kathleen E Corey; Nikroo Hashemi; Peter Carolan; Alan C Mullen; Michael Thiim; Irun Bhan; Ryan Nipp; Joseph Greer; Jennifer Temel; Raymond T Chung; Areej El-Jawahri
Journal:  Liver Transpl       Date:  2019-05-03       Impact factor: 5.799

Review 2.  Nonsurgical options for localized hepatocellular carcinoma.

Authors:  John Ha; Robert J Wong
Journal:  Clin Liver Dis (Hoboken)       Date:  2017-10-31

3.  Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease.

Authors:  Nneka N Ufere; John Donlan; Lauren Waldman; Jules L Dienstag; Lawrence S Friedman; Kathleen E Corey; Nikroo Hashemi; Peter Carolan; Alan C Mullen; Michael Thiim; Irun Bhan; Ryan Nipp; Joseph A Greer; Jennifer S Temel; Raymond T Chung; Areej El-Jawahri
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-15       Impact factor: 11.382

4.  Outcomes of Palliative Care Consultations for Hospitalized Patients With Liver Disease.

Authors:  Nneka N Ufere; David L O'Riordan; Kara E Bischoff; Angela K Marks; Nwamaka Eneanya; Raymond T Chung; Vicki Jackson; Steven Z Pantilat; Areej El-Jawahri
Journal:  J Pain Symptom Manage       Date:  2019-07-19       Impact factor: 3.612

5.  Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease.

Authors:  Adeyinka Charles Adejumo; Donghee Kim; Umair Iqbal; Eric R Yoo; Brian C Boursiquot; George Cholankeril; Robert J Wong; Paul Y Kwo; Aijaz Ahmed
Journal:  J Palliat Med       Date:  2019-08-09       Impact factor: 2.947

6.  Palliative Care and Hospice Referrals in Patients with Decompensated Cirrhosis: What Factors Are Important?

Authors:  John H Holden; Hani Shamseddeen; Amy W Johnson; Benjamin Byriel; Kavitha Subramoney; Yao-Wen Cheng; Akira Saito; Marwan Ghabril; Naga Chalasani; Greg A Sachs; Eric S Orman
Journal:  J Palliat Med       Date:  2020-02-24       Impact factor: 2.947

7.  Utilization of palliative care in patients hospitalized with heart failure: A contemporary national perspective.

Authors:  Fahad Alqahtani; Sudarshan Balla; Ahmad Almustafa; George Sokos; Mohamad Alkhouli
Journal:  Clin Cardiol       Date:  2018-12-15       Impact factor: 2.882

Review 8.  Palliative care in liver disease: what does good look like?

Authors:  Hazel Woodland; Ben Hudson; Karen Forbes; Anne McCune; Mark Wright
Journal:  Frontline Gastroenterol       Date:  2019-09-10

9.  Health Care Utilization and End-of-Life Care Outcomes for Patients With Decompensated Cirrhosis Based on Transplant Candidacy.

Authors:  Nneka N Ufere; Jennifer L Halford; Joshua Caldwell; Min Young Jang; Sunil Bhatt; John Donlan; Janet Ho; Vicki Jackson; Raymond T Chung; Areej El-Jawahri
Journal:  J Pain Symptom Manage       Date:  2019-10-23       Impact factor: 3.612

10.  Access to Comprehensive Services for Advanced Liver Disease in the Veterans Health Administration.

Authors:  S Hunter Dunn; Shari S Rogal; Marissa M Maier; Maggie Chartier; Timothy R Morgan; Lauren A Beste
Journal:  Dig Dis Sci       Date:  2019-08-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.